ABCG2 p.Arg482Ser
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 11956086
[PubMed]
Allen JD et al: "A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance."
No.
Sentence
Comment
146
Clearly, the mouse Bcrp1 R482M and R482S mutants confer enhanced resistance to anthracyclines compared with the wild-type transporter.
X
ABCG2 p.Arg482Ser 11956086:146:35
status: VERIFIED149 Resistance to topotecan was at least 10-fold lower, relative to the anthracyclines and bisantrene, in the 88.6-derived R482M and R482S mutant lines, as was found for the human R482G mutant (13).
X
ABCG2 p.Arg482Ser 11956086:149:129
status: VERIFIED150 In this context it is also noteworthy that cell lines carrying either the R482M or R482S Bcrp1 mutants showed greatly reduced (and Ko143-reversible) accumulation of the dye rhodamine 123 (Fig. 3C), as was observed previously for the R482G and R482T mutants of human BCRP (13).
X
ABCG2 p.Arg482Ser 11956086:150:83
status: VERIFIED144 Clearly, the mouse Bcrp1 R482M and R482S mutants confer enhanced resistance to anthracyclines compared with the wild-type transporter.
X
ABCG2 p.Arg482Ser 11956086:144:35
status: NEW147 Resistance to topotecan was at least 10-fold lower, relative to the anthracyclines and bisantrene, in the 88.6-derived R482M and R482S mutant lines, as was found for the human R482G mutant (13).
X
ABCG2 p.Arg482Ser 11956086:147:129
status: NEW148 In this context it is also noteworthy that cell lines carrying either the R482M or R482S Bcrp1 mutants showed greatly reduced (and Ko143-reversible) accumulation of the dye rhodamine 123 (Fig. 3C), as was observed previously for the R482G and R482T mutants of human BCRP (13).
X
ABCG2 p.Arg482Ser 11956086:148:83
status: NEW
PMID: 12208758
[PubMed]
Volk EL et al: "Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance."
No.
Sentence
Comment
154
Similar results were also seen in murine Bcrp1 R482M and R482S mutants (32).
X
ABCG2 p.Arg482Ser 12208758:154:57
status: VERIFIED153 Similar results were also seen in murine Bcrp1 R482M and R482S mutants (32).
X
ABCG2 p.Arg482Ser 12208758:153:57
status: NEW
PMID: 12374800
[PubMed]
Ozvegy C et al: "Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation."
No.
Sentence
Comment
23
Interestingly, in some drug-selected mouse cell lines, mutation of the equipositional amino acid in mouse ABCG2 occurred, causing altered drug resistance profiles for the mutant variants R482S and R482M (21).
X
ABCG2 p.Arg482Ser 12374800:23:187
status: VERIFIED
PMID: 14566825
[PubMed]
Miwa M et al: "Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants."
No.
Sentence
Comment
8
Cells transfected with R482G- or R482S-BCRP cDNA showed less intracellular accumulation of [3 H]mitoxantrone than the wild-type BCRP-transfected cells.
X
ABCG2 p.Arg482Ser 14566825:8:33
status: VERIFIED13 A doxorubicin-resistant human breast cancer cell line MCF-7 AdVp3000 and a mitoxantrone-resistant human colon carcinoma cell line S1-M1-80 expressed R482T- and R482G-BCRP, respectively and showed high resistance to mitoxantrone and doxorubicin.5,6,13 Doxorubicin-resistant murine fibroblast cell lines also expressed R482M- or R482S-BCRP and showed high resistance to mitoxantrone and doxorubicin.14 We recently identified the substitution R482M in a doxorubicin-resistant human T cell line MT-4/DOX500.23 We made 32 mutant BCRP cDNAs with an amino acid substitution in the TMs and examined the effect of the substitutions on cellular drug resistance.
X
ABCG2 p.Arg482Ser 14566825:13:327
status: VERIFIED64 PA/R482N, PA/R482C, PA/R482M, PA/R482S, PA/R482T, PA/R482V, PA/R482A, PA/R482G, PA/R482E PA/R482W and PA/R482D (Group 2) showed higher degrees of resistance to mitoxantrone than to SN-38.
X
ABCG2 p.Arg482Ser 14566825:64:33
status: VERIFIED78 Anthracycline resistance of R482-mutant BCRP transfectants Resistance to anthracycline antibiotics of PA/R482G and PA/ R482S, typical members of Group 2 transfectants, was examined (Fig. 4).
X
ABCG2 p.Arg482Ser 14566825:78:119
status: VERIFIED80 PA/R482G and PA/R482S showed resistance to doxorubicin, epirubicin and daunorubicin, but not to aclarubicin (Fig. 4).
X
ABCG2 p.Arg482Ser 14566825:80:16
status: VERIFIED84 Estrone is the first physiological substrate that was shown to circumvents BCRP-mediated drug resistance.17 As shown in Table I, estrone effectively reversed mitoxantrone resistance and SN-38 resistance of PA/R482G, PA/R482S, PA/N557H, PA/N557D, PA/H630E and PA/H630L.
X
ABCG2 p.Arg482Ser 14566825:84:219
status: VERIFIED85 Estrone also reversed doxorubicin resistance of PA/ R482G and PA/R482S (Table II).
X
ABCG2 p.Arg482Ser 14566825:85:65
status: VERIFIED86 Similarly, fumitremorgin C, a well-known BCRP inhibitor, strongly reversed the mitoxantrone resistance and SN-38 resistance of PA/R482G, PA/R482S, PA/ N557H, PA/N557D, PA/H630E and PA/H630L (Table III).
X
ABCG2 p.Arg482Ser 14566825:86:140
status: VERIFIED88 Uptake of [3 H]mitoxantrone To confirm that the high mitoxantrone resistance of PA/R482G and PA/R482S is attributable to decreased drug accumulation, the uptake of [3 H]mitoxantrone in PA317, PA/WT2, PA/R482G and PA/R482S cells was examined. As shown in Figure 6, intracellular accumulation of [3 H]mitoxantrone was significantly lower in PA/ R482G and PA/R482S than in PA/WT2.
X
ABCG2 p.Arg482Ser 14566825:88:96
status: VERIFIEDX
ABCG2 p.Arg482Ser 14566825:88:216
status: VERIFIEDX
ABCG2 p.Arg482Ser 14566825:88:356
status: VERIFIED89 The [3 H]mitoxantrone uptake reached plateau levels in 4 hr. The results clearly showed that steady-state levels of mitoxantrone accumulation in PA/ R482S and R482G were lower than that in PA/WT2 (Fig. 6).
X
ABCG2 p.Arg482Ser 14566825:89:149
status: VERIFIED117 Mitoxantrone uptake in PA317 cells was 10-fold higher than that in PA/R482S or PA/R482G cells.
X
ABCG2 p.Arg482Ser 14566825:117:70
status: VERIFIED119 PA/R482S and PA/R482G cells show approximately 100-200-fold more resistance to mitoxantrone than the parental cells.
X
ABCG2 p.Arg482Ser 14566825:119:3
status: VERIFIED122 This concentration was much higher than the IC50 values of FIGURE 4 - Resistance to mitoxantrone, SN-38 and anthracyclines of R482-mutant BCRP transfectants. PA/WT2, PA/R482G and PA/ R482S were mixed populations of the transfected cells established after the 2-step selection with 120 ng/ml methotrexate and 1 ng/ml mitoxantrone.
X
ABCG2 p.Arg482Ser 14566825:122:183
status: VERIFIED123 PA317 (closed circle), PA/WT2 (open triangle), PA/ R482G (open square) or PA/R482S (open lozenge) cells were cultured for 5 days with increasing concentrations of anthracyclines.
X
ABCG2 p.Arg482Ser 14566825:123:77
status: VERIFIED131 PA/R482S or PA/R482G and transporter function might not be so efficient in the presence of such a high concentration of mitoxantrone.
X
ABCG2 p.Arg482Ser 14566825:131:3
status: VERIFIED135 MCF-7 AdVp3000 established by treating MCF-7 cells with 3 g/ml of doxorubicin and 5 g/ml of verapamil overexpressed R482T-BCRP.5,13 S1-M1-80 established by treating human colon carcinoma S1 cells with 80 M mitoxantrone overexpressed R482G-BCRP.6,13 These resistant cells exhibited high resistance to doxorubicin and mitoxantrone.5,6,13 We found recently that MT-4/DOX500 cells established by treating human T cell MT-4 cells with 500 ng/ml of doxorubicin overexpressed R482M-BCRP.23 Two doxorubicin-resistant murine fibroblast lines 88.6/D800-A and 88.6/D800-B overexpressed R482M-BCRP and R482S-BCRP, respectively.14 Another doxorubicin-resistant cell line KOT52/D800 from mouse fibroblasts co-expressed wild-type BCRP and R482M-BCRP.14 In addition to anthracyclines and mitoxantrone, cells transfected with R482-mutant BCRP cDNAs also showed high resistance to methotrexate.28 Theoretically, 9 FIGURE 6 - Accumulation of [3 H]mitoxantrone in R482-mutant BCRP transfectants. PA/WT2, PA/R482G and PA/R482S were mixed populations of the transfected cells established after the 2-step selection with 120 ng/ml methotrexate and 1 ng/ml mitoxantrone.
X
ABCG2 p.Arg482Ser 14566825:135:614
status: VERIFIEDX
ABCG2 p.Arg482Ser 14566825:135:1024
status: VERIFIED136 PA317 (closed circle), PA/WT2 (open triangle), PA/R482S (open lozenge) or PA/R482G (open square) cells were incubated at 37°C with 50 nM [3 H]mitoxantrone.
X
ABCG2 p.Arg482Ser 14566825:136:50
status: VERIFIED140 TABLE I - REVERSAL OF MITOXANTRONE RESISTANCE AND SN-38 RESISTANCE BY ESTRONE1 Cell line Degree of Mitoxantrone resistance Reversal index Degree of SN-38 resistance Reversal index Control 10 M estrone Control 10 M estrone PA/WT1 7.1 Ϯ 0.6 2.2 Ϯ 0.4 3.2 28 Ϯ 1 4.7 Ϯ 0.3 6.0 PA/R482S 120 Ϯ 20 6.8 Ϯ 0.4 18 37 Ϯ 2 4.4 Ϯ 1.1 8.4 PA/R482G 84 Ϯ 17 3.7 Ϯ 0.3 23 22 Ϯ 1 3.3 Ϯ 0.1 6.7 PA/N557H 3.3 Ϯ 0.1 1.0 Ϯ 0.1 3.3 4.8 Ϯ 0.5 3.4 Ϯ 0.1 1.4 PA/N557D 7.4 Ϯ 0.2 1.4 Ϯ 0.1 5.3 3.8 Ϯ 0.6 2.9 Ϯ 0.2 1.3 PA/H630E 5.8 Ϯ 0.2 1.1 Ϯ 0.1 5.3 20 Ϯ 2.8 6.0 Ϯ 0.1 3.3 PA/H630L 3.3 Ϯ 0.1 0.9 Ϯ 0.1 3.7 8.6 Ϯ 0.4 2.7 Ϯ 0.1 3.2 1 Cells were cultured in the absence or presence of 10 M estrone with increasing concentrations of mitoxantrone or SN-38. Degree of resistance is the ratio of the IC50 value for BCRP-expressing cells divided by that for parental PA317.
X
ABCG2 p.Arg482Ser 14566825:140:317
status: VERIFIED141 The reversal index is calculated by dividing degree of resistance without estrone by that with estrone. TABLE II - REVERSAL OF DOXORUBICIN RESISTANCE BY ESTRONE Cell line Degree of Doxorubicin resistance Reversal index Control 10 M Estrone PA/WT1 1.2 Ϯ 0.1 1.0 Ϯ 0.0 1.2 PA/R482S 10 Ϯ 1 1.3 Ϯ 0.1 7.7 PA/R482G 8.0 Ϯ 0.6 1.2 Ϯ 0.1 6.7 These cells were cultured in the absence or presence of 10 M estrone with increasing concentrations of doxorubicin.
X
ABCG2 p.Arg482Ser 14566825:141:294
status: VERIFIED143 The reversal index is calculated by dividing degree of resistance without estrone by that with estrone. TABLE III - REVERSAL OF MITOXANTRONE RESISTANCE AND SN-38 RESISTANCE BY FUMITREMORGIN C1 Cell line Degree of Mitoxantrone resistance Reversal index Degree of SN-38 resistance Reversal index Control 3 M Fumitremorgin C Control 3 M Fumitremorgin C PA/WT1 11 Ϯ 1 1.0 Ϯ 0.1 11 23 Ϯ 1 1.1 Ϯ 0.1 21 PA/R482S 140 Ϯ 10 1.2 Ϯ 0.1 120 41 Ϯ 1 0.9 Ϯ 0.1 46 PA/R482G 89 Ϯ 21 0.9 Ϯ 0.1 99 17 Ϯ 2 0.9 Ϯ 0.1 19 PA/N557H 3.3 Ϯ 0.1 1.0 Ϯ 0.1 3.3 4.8 Ϯ 0.5 1.1 Ϯ 0.1 4.4 PA/N557D 7.4 Ϯ 0.2 0.8 Ϯ 0.0 9.3 3.8 Ϯ 0.6 1.2 Ϯ 0.1 3.2 PA/H630E 5.8 Ϯ 0.2 1.1 Ϯ 0.1 5.3 20 Ϯ 2.8 1.4 Ϯ 0.1 14 PA/H630L 3.3 Ϯ 0.1 0.9 Ϯ 0.1 3.7 8.6 Ϯ 0.4 1.4 Ϯ 0.1 6.1 1 These cells were cultured in the absence or presence of 3 M fumitremorgin C with increasing concentrations of mitoxantrone or SN-38. Degree of resistance is the ratio of IC50 value for BCRP-expressing cells divided by that for parental PA317.
X
ABCG2 p.Arg482Ser 14566825:143:440
status: VERIFIED147 Cells transfected with R482G- (GGG), R482M- (ATG), R482T- (ACG), or R482S- (AGT and AGC) BCRP cDNA showed greater resistance to mitoxantrone and doxorubicin than PA/WT2 (Fig. 2).
X
ABCG2 p.Arg482Ser 14566825:147:68
status: VERIFIED148 As described above, human drug-resistant cell lines MCF-7 AdVp3000, S1-M1-80, MT-4/DOX500 and a mouse drug-resistant line 88.6/D800-B overexpressed R482T- (ACG), R482G- (GGG), R482M- (ATG) and R482S- (AGT) BCRP, respectively.5,6,13,14,23 The other possible mutations are R482W (TGG) and R482K (AAG).
X
ABCG2 p.Arg482Ser 14566825:148:193
status: VERIFIED149 PA317 cells expressing R482W- BCRP (PA/R482W) showed somewhat higher levels of resistance to mitoxantrone and doxorubicin than PA/WT2, but the resistance levels were lower than those in PA/ R482G, PA/R482M, PA/R482T and PA/R482S.
X
ABCG2 p.Arg482Ser 14566825:149:223
status: VERIFIED163 Group 2 members (PA/R482N, PA/R482C, PA/R482M, PA/R482S, PA/R482T, PA/R482V, PA/ R482A, PA/R482G, PA/R482E PA/R482W and PA/R482D) showed higher degrees of resistance to mitoxantrone than to SN-38.
X
ABCG2 p.Arg482Ser 14566825:163:50
status: VERIFIED
PMID: 14612912
[PubMed]
Robey RW et al: "Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity."
No.
Sentence
Comment
133
Mutations at amino-acid 482 have included R482G and R482T in human cancer cells; R482S and R482M in mouse fibroblast lines (Honjo et al, 2001; Allen et al, 2002); and a recently reported R482M mutation in a doxorubicin-selected human T-cell line (Wang et al, 2003).
X
ABCG2 p.Arg482Ser 14612912:133:81
status: VERIFIED152 The findings presented here parallel those of Allen et al, (2002), who described two mutations, R482M and R482S, in mouse fibroblast cells lacking functional Mdr1, Mdr2, and Mrp1.
X
ABCG2 p.Arg482Ser 14612912:152:106
status: VERIFIED
No.
Sentence
Comment
119
The mutants having R482G or R482T (R482M or R482S in the mouse abcg2) showed altered substrate specificity as compared to the wild-type protein, i.e., they conferred increased mitoxantrone or doxorubicin (DOX) resistance and rhodamine 123 transport capacity (see Fig. 2, [42,43]).
X
ABCG2 p.Arg482Ser 15165903:119:44
status: VERIFIED
PMID: 15670731
[PubMed]
Ozvegy-Laczka C et al: "Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition."
No.
Sentence
Comment
48
The two internal complementary primer pairs containing the specific mutation were: 5V-tta tta cca atg atc atg tta cc-3Vand 5-Vgg taa cat gat cat tgg taa taa-3V (R482I), 5V-tta tca gat cta tta ccc atg-3Vand 5V-gg taa cat cat cat ggg taa t-3V(R482M), 5V-ta ccc atg tcg atg tta cca a-3Vand 5V-t tgg taa cat cga cat ggg ta-3V(R482S), 5V-cc atg gac atg tta cca tcg att ata-3V and 5V-tat aat cga tgg taa cat gtc cat gg-3V (R482D), 5V-atg tta cca tcg att ata ttt acc-3Vand 5V-cc atg aat atg tta cca tcg att ata-3V (R482N), 5V-tta tta cct atg aag atg tta-3V cc and 5V-gg taa cat ctt cat agg taa taa-3V(R482K) and 5V-tta tta cct atg tac atg tta cc-3Vand 5V-gg taa cat gta cat agg taa taa-3V (R482Y).
X
ABCG2 p.Arg482Ser 15670731:48:322
status: VERIFIED
PMID: 16108826
[PubMed]
Sugimoto Y et al: "Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics."
No.
Sentence
Comment
64
Cells transfected with R482G-BCRP or R482S-BCRP cDNA showed less intracellular accumulation of 3 H-mitoxantrone than wild-type BCRP-transfected cells.
X
ABCG2 p.Arg482Ser 16108826:64:37
status: VERIFIED
PMID: 16158227
[PubMed]
Krishnamurthy P et al: "The ABC transporter Abcg2/Bcrp: role in hypoxia mediated survival."
No.
Sentence
Comment
115
The mutants having R482G or R482T (R482M or R482S in the mouse Bcrp) showed altered transport properties as compared to the wild-type protein (Honjo et al. 2001; Allen et al. 2002).
X
ABCG2 p.Arg482Ser 16158227:115:44
status: VERIFIED
PMID: 16166320
[PubMed]
Shafran A et al: "ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates."
No.
Sentence
Comment
22
Sequencing of the Abcg2 gene in these drug-resistant cell lines identified two mutations, R482M and R482S.
X
ABCG2 p.Arg482Ser 16166320:22:100
status: VERIFIED
PMID: 16337740
[PubMed]
Cervenak J et al: "The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology."
No.
Sentence
Comment
81
Moreover, in the 88.6/D800-A, 88.6/D800-B and KOT52/ D800 mouse fibroblast cell lines, an R482M (KOT52/D800 and 88.6/D800-A cells) and an R482S (88.6/D800-B cells) mutation was observed, with a similar, anthracycline resistant phenotype [42].
X
ABCG2 p.Arg482Ser 16337740:81:138
status: VERIFIED
PMID: 17015488
[PubMed]
Sarkadi B et al: "Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system."
No.
Sentence
Comment
804
Interestingly, the same phenomenon was observed in the case of the mouse Abcg2 protein; drug selection induced a mutation exactly at the same position (R482M or R482S in the mouse Abcg2), similarly altering the substrate handling of this ortholog (5).
X
ABCG2 p.Arg482Ser 17015488:804:161
status: VERIFIED
PMID: 20345483
[PubMed]
Kawahara H et al: "Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene."
No.
Sentence
Comment
5
These inhibitory effects of sunitinib were further analyzed in Q141K-, R482G-, R482S-, and F431L-variant BCRPs.
X
ABCG2 p.Arg482Ser 20345483:5:79
status: VERIFIED173 Reversal ratios are shown for wild-type (gray circles), and Q141K (open squares), F431L (filled circles), R482S (open diamonds), and R482G (open triangles) BCRP variant-expressing cells.
X
ABCG2 p.Arg482Ser 20345483:173:106
status: VERIFIED
PMID: 24384916
[PubMed]
Telbisz A et al: "Regulation of the function of the human ABCG2 multidrug transporter by cholesterol and bile acids: effects of mutations in potential substrate and steroid binding sites."
No.
Sentence
Comment
225
These were the R482G and R482S variants, which are fully active already at low membrane cholesterol levels, and the R482K and R482I mutants, which show similar cholesterol-sensing capability to the wtABCG2 (see earlier).
X
ABCG2 p.Arg482Ser 24384916:225:25
status: NEW237 4, C and D, and 6A), in the case of the R482G or S variants low concentrations of CA did not significantly alter ABCG2-ATPase activity; however, when we used higher bile acid concentrations (above 0.5 mM), both baseline and substrate-stimulated ATPase activities decreased (see Fig. 6B for the R482G mutant; R482S is not shown).
X
ABCG2 p.Arg482Ser 24384916:237:308
status: NEW